These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39422764)

  • 21. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
    Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
    Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
    J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipilimumab and Bevacizumab in Glioblastoma.
    Carter T; Shaw H; Cohn-Brown D; Chester K; Mulholland P
    Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):622-626. PubMed ID: 27169593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
    BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
    Ahluwalia MS; Ozair A; Drappatz J; Ye X; Peng S; Lee M; Rath S; Dhruv H; Hao Y; Berens ME; Walbert T; Holdhoff M; Lesser GJ; Cloughesy TF; Sloan AE; Takebe N; Couce M; Peereboom DM; Nabors B; Wen PY; Grossman SA; Rogers LR
    Clin Cancer Res; 2024 Aug; 30(15):3167-3178. PubMed ID: 38836759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
    Jin Y; Chen DL; Wang F; Yang CP; Chen XX; You JQ; Huang JS; Shao Y; Zhu DQ; Ouyang YM; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH; Zhang DS
    Mol Cancer; 2020 Oct; 19(1):154. PubMed ID: 33126883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
    Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
    Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
    Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.
    Xu Y; Xiong F; Li H; Zheng H; Jiang J; Li Q; Li G; Zhao W; Li R; Li J; Xie R; An R; Zhang H; Gao Q
    Int J Gynecol Cancer; 2024 Sep; 34(9):1461-1465. PubMed ID: 38658024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.